Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus

Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit

“…GOG has recently conducted a new phase III trial to compare paclitaxel plus carboplatin and paclitaxel plus ifosfamide in chemotherapy-naive patients with newly diagnosed stage I-IV persistent or recurrent carcinosarcoma (GOG 261). We have determined from our clinical experience with 6 Japanese patients with advanced or recurrent uterine carcinosarcoma that paclitaxel and carboplatin is a feasible and effective chemotherapy combination [23]. Moreover, although the number of enrolled patients did not reach the designed sample size, we recently reported results of a phase II study to evaluate the effects of paclitaxel and [24].…”

Prognoses and Prognostic Factors of Carcinosarcoma, Endometrial Stromal Sarcoma and Uterine Leiomyosarcoma: A Comparison with Uterine Endometrial Adenocarcinoma

“…Given the similarities between CS and endometrial carcinoma, it is logical to assume that a chemotherapeutic regimen designed for endometrial cancer would also be effective for CS [28]. Indeed, we reported that the combination of paclitaxel and carboplatin demonstrated higher activity with less toxicity than standard regimens in patients with advanced or recurrent CS [58]. Although the number of cases was small, the results of this trial argue for the conversion/metaplastic theory of CS, which behaves differently from other uterine sarcomas.…”

Concurrent Radiochemotherapy of Locally Recurrent or Advanced Sarcomas of the Uterus

“…Paclitaxel achieves a response in 9% of highly advanced or recurrent leiomyosarcomas [30]. Paclitaxel combined with carboplatin was effective in carcinosarcomas of the uterus [37].…”